Global Overt Hepatic Encephalopathy Market Growth (Status and Outlook) 2023-2029

Global Overt Hepatic Encephalopathy Market Growth (Status and Outlook) 2023-2029

Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma.

LPI (LP Information)' newest research report, the “Overt Hepatic Encephalopathy Industry Forecast” looks at past sales and reviews total world Overt Hepatic Encephalopathy sales in 2022, providing a comprehensive analysis by region and market sector of projected Overt Hepatic Encephalopathy sales for 2023 through 2029. With Overt Hepatic Encephalopathy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Overt Hepatic Encephalopathy industry.

This Insight Report provides a comprehensive analysis of the global Overt Hepatic Encephalopathy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Overt Hepatic Encephalopathy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Overt Hepatic Encephalopathy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Overt Hepatic Encephalopathy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Overt Hepatic Encephalopathy.

The global Overt Hepatic Encephalopathy market size is projected to grow from US$ 49 million in 2022 to US$ 77 million in 2029; it is expected to grow at a CAGR of 6.6% from 2023 to 2029.

Overt hepatic encephalopathy develops in approximately 40% of patients with cirrhosis during their clinical care. A first episode of overtencephalopathy predicts recurrence in 40% of patients. Aggravating factors for the development of hepatic encephalopathy in advanced liver disease include infection, gastrointestinal bleeding, metabolic disturbance, and receipt of sedative medications. Genetic abnormalities affecting ammonia metabolism can also play a role.

This report presents a comprehensive overview, market shares, and growth opportunities of Overt Hepatic Encephalopathy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Type A (Acute Liver Failure)
Type B (Portal Systemic Bypass Without Liver Disease)
Type C (Liver Cirrhosis)

Segmentation by application
Hospitals
Research Institutes
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alfa Wassermann
Cosmo Pharmaceuticals
Horizon Pharma
KannaLife Sciences
Ocer Therapeutics
Rebiotix
Spherium Biomed
Umecrine Cognition
ASKA Pharmaceutical
Mallinckrodt
Valeant

Please note: The report will take approximately 2 business days to prepare and deliver.